全文获取类型
收费全文 | 37719篇 |
免费 | 3440篇 |
国内免费 | 472篇 |
专业分类
耳鼻咽喉 | 202篇 |
儿科学 | 1906篇 |
妇产科学 | 899篇 |
基础医学 | 3348篇 |
口腔科学 | 285篇 |
临床医学 | 4038篇 |
内科学 | 11183篇 |
皮肤病学 | 684篇 |
神经病学 | 2958篇 |
特种医学 | 510篇 |
外科学 | 4387篇 |
综合类 | 1642篇 |
现状与发展 | 1篇 |
一般理论 | 9篇 |
预防医学 | 3406篇 |
眼科学 | 1558篇 |
药学 | 1689篇 |
3篇 | |
中国医学 | 238篇 |
肿瘤学 | 2685篇 |
出版年
2024年 | 67篇 |
2023年 | 545篇 |
2022年 | 366篇 |
2021年 | 629篇 |
2020年 | 590篇 |
2019年 | 246篇 |
2018年 | 948篇 |
2017年 | 949篇 |
2016年 | 1073篇 |
2015年 | 1020篇 |
2014年 | 919篇 |
2013年 | 1315篇 |
2012年 | 2691篇 |
2011年 | 3035篇 |
2010年 | 1358篇 |
2009年 | 1280篇 |
2008年 | 2994篇 |
2007年 | 2863篇 |
2006年 | 2444篇 |
2005年 | 2641篇 |
2004年 | 3043篇 |
2003年 | 2920篇 |
2002年 | 2290篇 |
2001年 | 1801篇 |
2000年 | 538篇 |
1999年 | 408篇 |
1998年 | 476篇 |
1997年 | 368篇 |
1996年 | 201篇 |
1995年 | 141篇 |
1994年 | 142篇 |
1993年 | 135篇 |
1992年 | 129篇 |
1991年 | 81篇 |
1990年 | 88篇 |
1989年 | 89篇 |
1988年 | 84篇 |
1987年 | 78篇 |
1986年 | 67篇 |
1985年 | 42篇 |
1984年 | 44篇 |
1983年 | 30篇 |
1982年 | 35篇 |
1981年 | 40篇 |
1980年 | 25篇 |
1979年 | 17篇 |
1975年 | 16篇 |
1974年 | 23篇 |
1970年 | 16篇 |
1968年 | 17篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Characteristics of hyperparathyroid states in the Canadian multicentre osteoporosis study (CaMos) and relationship to skeletal markers 下载免费PDF全文
2.
3.
Parallel enzyme‐linked immunosorbent assay screening for human immunodeficiency virus among blood donors in five Chinese blood centres: a retrospective analysis 下载免费PDF全文
4.
5.
6.
María Cabrerizo Gloria Trallero María José Pena Amaia Cilla Gregoria Megias Carmen Mu?oz-Almagro Eva Del Amo Diana Roda Ana Isabel Mensalvas Antonio Moreno-Docón Juan García-Costa Nuria Rabella Manuel Ome?aca María Pilar Romero Sara Sanbonmatsu-Gámez Mercedes Pérez-Ruiz María José Santos-Mu?oz Cristina Calvo And the study group of “Enterovirus parechovirus infections in children under ?years-old Spain” PI- 《European journal of pediatrics》2015,174(11):1511-1516
7.
Comparative safety study on severe anemia by simeprevir versus telaprevir‐based triple therapy for chronic hepatitis C 下载免费PDF全文
Eiichi Ogawa Norihiro Furusyo Eiji Kajiwara Hideyuki Nomura Akira Kawano Kazuhiro Takahashi Kazufumi Dohmen Takeaki Satoh Koichi Azuma Makoto Nakamuta Toshimasa Koyanagi Kazuhiro Kotoh Shinji Shimoda Jun Hayashi The Kyushu University Liver Disease Study Group 《Journal of gastroenterology and hepatology》2015,30(8):1309-1316
8.
GIUSEPPE BORIANI MAURO BIFFI MAURIZIO RUSSO† MAURIZIO LUNATI‡ GIANLUCA BOTTO¶ ALESSANDRO PROCLEMER§ GIUSEPPE VERGARA WERNER RAHUE†† CRISTIAN MARTIGNANI RENATO RICCI† MASSIMO SANTINI† On Behalf of the SEARCH MI Registry Italian Investigators 《Pacing and clinical electrophysiology : PACE》2006,29(S2):S29-S34
Background: Large randomized trials show that in appropriately selected patients with left ventricular dysfunction, implantable cardioverter-defibrillators (ICDs) can improve overall survival at 2–5 years. Since direct implementation of the criteria used in the MADIT II and SCD-HeFT will lead to a marked rise in ICD implants, there is a growing fear that increased use of ICDs may cause a dramatic burden to health care systems. The ICD has traditionally been seen as an expensive form of treatment, which is difficult to accept at the first look. This is mainly due to the nonlinear character of the ICD investment, characterized by high initial expenditure, followed by a deferred pay-off in terms of clinical benefits. Cost-effectiveness analysis may help provide a different perspective on the problem of ICD cost, as may estimation of the daily cost of ICD treatment, assuming a time horizon of 5–7 years—a particularly interesting subject for further registry studies.
Methods and Results: Based on real expenditure data from 2002 to 2005, as recorded in the Search-MI Registry-Italian Sub-study of patients implanted on MADIT II indications, we estimated the daily costs associated with the device and leads. Over a 5–7 year time horizon, the average daily cost was estimated to be €4.60–€6.70. Translation of these figures into U.S. market conditions suggests a daily cost of around $7.90–$11.40.
Conclusions: These findings appear useful to help evaluate the affordability of ICD in comparison with other therapeutic options in a context of limited available economic resources. 相似文献
Methods and Results: Based on real expenditure data from 2002 to 2005, as recorded in the Search-MI Registry-Italian Sub-study of patients implanted on MADIT II indications, we estimated the daily costs associated with the device and leads. Over a 5–7 year time horizon, the average daily cost was estimated to be €4.60–€6.70. Translation of these figures into U.S. market conditions suggests a daily cost of around $7.90–$11.40.
Conclusions: These findings appear useful to help evaluate the affordability of ICD in comparison with other therapeutic options in a context of limited available economic resources. 相似文献
9.
10.
Prevention of Bone Loss by Clodronate in Early Postmenopausal Women with Vertebral Osteopenia: A Dose-Finding Study 总被引:1,自引:0,他引:1
M. J. V?lim?ki K. Laitinen K. Laitinen A. Patronen H. Puolijoki H. Puolijoki J. Sepp?nen L. Pylkk?nenand the Probone Study Group 《Osteoporosis international》2002,13(12):937-947
This double-masked, placebo-controlled study was undertaken to determine the efficacy and safety of oral clodronate in the
prevention of bone loss in early postmenopausal women with vertebral osteopenia. Altogether 610 women with a mean age of 53
years were recruited for the study. They were 1–5 years postmenopausal and their lumbar spine bone mineral density (BMD) was
at least 1 standard deviation below the mean of premenopausal women (T-score ≤−1). The subjects were randomized into five study groups to receive either placebo, clodronate 65 mg, 400 mg or 800
mg daily, or intermittent clodronate in 3 month cycles with 400 mg daily for 15 days followed with no treatment for 75 days
for 3 years. One hundred and eighty-seven of 509 women who completed the primary study continued in the extension study of
2 years in which previous placebo users were switched to clodronate 800 mg daily, while previous users of 400 mg or 800 mg
of clodronate used either placebo or 800 mg of clodronate daily. In the primary study clodronate was administered in the evening,
and in the extension 1 h before breakfast on an empty stomach. In the primary study mean changes in lumbar spine BMD were
−3.4% in the placebo group and +0.4% in 800 mg clodronate group [difference between groups at 3 years 3.8% (95% CI 2.7% to
4.9%, p<0.0001)], and in the trochanter area BMD −1.1% in the placebo group, and + 0.4% in the 800 mg clodronate group [difference
between groups at 3 years 1.5% (95% CI 0.05% to 2.9%)]. During the extension study mean changes in lumbar spine BMD were +1.5%
in the clodronate group and −0.2 % in the placebo group [difference between groups 1.7% (CI 0.4% to 3.0%, p = 0.010)] and in trochanter BMD were +2.5% in the clodronate group and no change in the placebo group [difference between
groups 2.1% (CI 0.3% to 3.9%, p = 0.007)]. No statistically significant differences between the placebo and 800 mg clodronate groups were found in the femoral
neck BMD. In the primary study the urinary excretion of type I collagen aminoterminal telopeptide (NTX) decreased by 44% (p<0.0001 compared with placebo) and that of deoxypyridinoline by 18% (p<0.0001) in the clodronate 800 mg group. In the extension study urinary NTX decreased by 51% (p<0.0001) in those who were switched to 800 mg of clodronate and increased by 67% (p<0.0001) in those who stopped using that dose. There was no difference in the frequency of gastrointestinal complaints between
clodronate- and placebo-treated patients in the primary study, but they were more common among women who received clodronate
in the extension phase. Clodronate in daily doses of 400–800 mg caused a slight elevation of aminotransferase levels, usually
within the reference range. In bone biopsies no defect in mineralization was found. In conclusion, clodronate in a daily dose
of 800 mg prevents early postmenopausal bone loss at the sites of the skeleton in which cancellous bone predominates. It effectively
reduces bone resorption and bone turnover rate. Antifracture efficacy of clodronate remains to be established by prospective,
placebo-controlled trials.
Received: 4 March 2002 / Accepted: 9 July 2002 相似文献